Amphastar Pharmaceuticals (NASDAQ:AMPH) Sets New 1-Year Low - Should You Sell?

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report)'s stock price hit a new 52-week low during trading on Monday . The stock traded as low as $35.54 and last traded at $35.54, with a volume of 76329 shares traded. The stock had previously closed at $36.30.

Wall Street Analyst Weigh In

AMPH has been the subject of several research analyst reports. StockNews.com downgraded Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, November 1st. Wells Fargo & Company began coverage on Amphastar Pharmaceuticals in a research report on Friday, November 22nd. They issued an "equal weight" rating and a $55.00 price target for the company. Three analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, Amphastar Pharmaceuticals has an average rating of "Hold" and an average target price of $60.33.

Amphastar Pharmaceuticals Price Performance

The company has a 50-day moving average of $43.63 and a 200-day moving average of $44.32. The stock has a market capitalization of $1.70 billion, a price-to-earnings ratio of 11.81, a P/E/G ratio of 0.87 and a beta of 0.82. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43.

Insider Activity

In other Amphastar Pharmaceuticals news, EVP Rong Zhou sold 6,893 shares of the business's stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $48.88, for a total value of $336,929.84. Following the completion of the transaction, the executive vice president now directly owns 118,388 shares in the company, valued at approximately $5,786,805.44. The trade was a 5.50 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Richard K. Prins sold 5,000 shares of the firm's stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $48.80, for a total value of $244,000.00. Following the sale, the director now owns 31,471 shares in the company, valued at $1,535,784.80. This trade represents a 13.71 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 41,533 shares of company stock worth $1,987,482 over the last three months. 27.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the business. Boston Trust Walden Corp acquired a new position in shares of Amphastar Pharmaceuticals during the 3rd quarter valued at about $26,189,000. Millennium Management LLC raised its stake in Amphastar Pharmaceuticals by 84.6% during the second quarter. Millennium Management LLC now owns 738,748 shares of the company's stock worth $29,550,000 after purchasing an additional 338,653 shares during the period. Epoch Investment Partners Inc. boosted its holdings in shares of Amphastar Pharmaceuticals by 35.1% in the 2nd quarter. Epoch Investment Partners Inc. now owns 1,078,852 shares of the company's stock valued at $43,154,000 after purchasing an additional 280,390 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of Amphastar Pharmaceuticals during the 2nd quarter valued at $9,085,000. Finally, Hotchkis & Wiley Capital Management LLC acquired a new stake in shares of Amphastar Pharmaceuticals during the 3rd quarter worth $10,804,000. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.